INDVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Indivior Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$33.87+1.42 (+4.38%)
Close on Oct 19, 2026
- Market cap
- $4.20B
- P/E (TTM)
- 12.2
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2020 to 2025
Gross margin
80.2%
Operating margin
21.1%
Net margin
16.9%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.3% | +11.2% | – | – | |
| Gross profit | +3.9% | +9.9% | – | – | |
| Operating income | +589.5% | – | – | – | |
| Net income | +2900.0% | – | – | – | |
| EPS, diluted | +3180.0% | – | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -96.6% | |
| Return on assets | – | – | 16.7% | |
| Current ratio | – | – | 0.71 | |
| Debt to equity | – | – | -3.26 | |
| Net debt to EBITDA | – | – | 0.46× | |
| Interest coverage | – | – | 5.8× | |
| Inventory turnover | – | – | 1.5× | |
| Capex to revenue | – | – | 5.3% | |
| Diluted shares | – | – | 128M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Indivior Pharmaceuticals generated $720.00M from operations and spent $520.00M on capital expenditure, dividends and share buybacks. 22% of that went back into the business.
Generated
$720.00M
Used
$520.00M
Capital expenditure$112.00M22%Dividends$00%Share buybacks$408.00M78%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin16.9%
×Asset turnover0.98×
×Equity multiplier-5.79×
=Return on equity, FY2025-96.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 16.9% | 0.98× | -5.79× | -96.6% |
| FY2024 | 0.6% | 0.77× | -5.90× | -2.7% |
| FY2023 | -11.5% | 0.62× | -17.72× | 126.6% |
| FY2022 | -4.7% | 0.50× | 33.97× | -79.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$210.00M
- Cash generatingOperating cash flow above zero-$27.00M
- Return on assets improvedROA up on the prior year0.4% → 16.0%
- Earnings backed by cashOperating cash flow above net income-$27.00M vs $210.00M
- Less leverageLong-term debt to assets fell23.9% → 24.1%
- Better liquidityCurrent ratio rose0.90 → 0.71
- No dilutionShare count did not rise133M → 128M
- Gross margin improvedGross margin up on the prior year80.56% → 80.23%
- More efficientAsset turnover rose0.68 → 0.94